Form 8-K - Current report:
SEC Accession No. 0000950170-25-051441
Filing Date
2025-04-07
Accepted
2025-04-07 12:36:52
Documents
13
Period of Report
2025-04-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K neog-20250404.htm   iXBRL 8-K 52453
2 EX-10.1 neog-ex10_1.htm EX-10.1 2221607
3 EX-99.1 neog-ex99_1.htm EX-99.1 9129
  Complete submission text file 0000950170-25-051441.txt   2705251

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT neog-20250404.xsd EX-101.SCH 25023
15 EXTRACTED XBRL INSTANCE DOCUMENT neog-20250404_htm.xml XML 4730
Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 8-K | Act: 34 | File No.: 000-17988 | Film No.: 25817171
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)